{
    "nct_id": "NCT03336216",
    "official_title": "A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer",
    "inclusion_criteria": "* Must have histological or cytological confirmed diagnosis of locally advanced or metastatic adenocarcinoma of the pancreas, which has progressed on or after one line of chemotherapy\n* ECOG Performance status 0-1\n* Adequate organ functions\n* Measurable disease\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Suspected or known CNS metastasis\n* Participants with active, known, or suspected autoimmune disease\n* Uncontrolled or significant cardiovascular disease\n* Prior exposure to selected immune cell-modulating antibody regimens",
    "miscellaneous_criteria": ""
}